NASDAQ:KRYS Krystal Biotech - KRYS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $84.22 +0.24 (+0.29%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$82.63▼$85.2150-Day Range$71.03▼$84.2752-Week Range$47.67▼$85.65Volume97,870 shsAverage Volume199,046 shsMarket Capitalization$2.17 billionP/E RatioN/ADividend YieldN/APrice Target$106.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Krystal Biotech MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside26.8% Upside$106.75 Price TargetShort InterestBearish5.44% of Float Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.84Based on 5 Articles This WeekInsider TradingSelling Shares$5.85 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.36) to ($4.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.35 out of 5 starsMedical Sector275th out of 1,049 stocksBiological Products, Except Diagnostic Industry48th out of 170 stocks 3.3 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $106.75, Krystal Biotech has a forecasted upside of 26.8% from its current price of $84.22.Amount of Analyst CoverageKrystal Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.44% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Krystal Biotech has recently increased by 14.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 3.2 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Krystal Biotech this week, compared to 1 article on an average week.Search Interest9 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,848,121.00 in company stock.Percentage Held by Insiders17.80% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.80% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow in the coming year, from ($5.36) to ($4.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is -16.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is -16.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Krystal Biotech (NASDAQ:KRYS) StockKrystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.Read More Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address KRYS Stock News HeadlinesJanuary 29, 2023 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) Short Interest UpdateJanuary 23, 2023 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 10.2% in DecemberJanuary 29, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 22, 2023 | americanbankingnews.comInsider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 22,148 Shares of StockJanuary 20, 2023 | seekingalpha.comKrystal Biotech: Reached My Price Target, Waiting For A DropJanuary 20, 2023 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) CEO Krish S. Krishnan Sells 22,149 SharesJanuary 18, 2023 | finance.yahoo.comKrystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic FibrosisJanuary 10, 2023 | msn.comFDA extends review of Krystal's topical gene therapy for skin disorder citing manufacturing dataJanuary 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 9, 2023 | finance.yahoo.comKrystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDAJanuary 9, 2023 | markets.businessinsider.comKrystal Biotech Announces FDA's 3-Month Extension Of BLA PDUFA Date And Regulatory Update For B-VECJanuary 9, 2023 | finance.yahoo.comKrystal Biotech’s stock is down on delayed PDUFA dateJanuary 9, 2023 | finance.yahoo.comKrystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis BullosaDecember 16, 2022 | finance.yahoo.comBofA Securities: The most promising biotech stocks in 2023December 15, 2022 | finance.yahoo.comKrystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of MedicineDecember 14, 2022 | finance.yahoo.comNew England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis BullosaDecember 12, 2022 | finance.yahoo.com12 Best Small-Cap Healthcare Stocks To Buy NowDecember 6, 2022 | finance.yahoo.com2 Risky Stocks That Could Soar in 2023December 5, 2022 | finance.yahoo.comJeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic ConferenceDecember 1, 2022 | finance.yahoo.comKrystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap ConferenceNovember 23, 2022 | finance.yahoo.comKrystal Biotech to Present at 5th Annual Evercore ISI HealthCONx ConferenceNovember 17, 2022 | msn.comKrystal Biotech's Subsidiary Posts Durability Data For Fine Line, WrinklesNovember 17, 2022 | finance.yahoo.comJeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and WrinklesNovember 13, 2022 | seekingalpha.comVertex: High Growth For Years AheadNovember 7, 2022 | thestreet.comKrystal Biotech Needs to Feed the Goldfish in 2023November 7, 2022 | finanznachrichten.deKrystal Biotech, Inc.: Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational HighlightsNovember 7, 2022 | msn.comRecap: Krystal Biotech Q3 EarningsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address KRYS Company Calendar Last Earnings11/07/2022Today1/29/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees119Year FoundedN/APrice Target and Rating Average Stock Price Forecast$106.75 High Stock Price Forecast$133.00 Low Stock Price Forecast$74.00 Forecasted Upside/Downside+26.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,570,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-18.68% Return on Assets-17.30% Debt Debt-to-Equity RatioN/A Current Ratio14.18 Quick Ratio14.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$26.69 per share Price / Book3.16Miscellaneous Outstanding Shares25,750,000Free Float21,165,000Market Cap$2.17 billion OptionableNot Optionable Beta0.84 Key ExecutivesMr. Krish S. Krishnan M.B.A. (Age 58)M.S., Founder, Chairman, Pres & CEO Comp: $1.01MMs. Suma M. Krishnan (Age 58)Founder, COO, Pres of R&D and Director Comp: $708.56kMs. Kathryn A. Romano (Age 41)Exec. VP & Chief Accounting Officer Comp: $452.43kDr. Andreas C. Orth (Age 53)Exec. VP & Chief Commercial Officer Comp: $549.17kMs. Gloria LinAccounting Mang.Mr. Ram KamineniSr. VP of CMC & Technical OperationsMs. Meg DodgeVP of Investor Relations & Corp. CommunicationsMr. David GlynnGen. Counsel, Commercial & ComplianceMr. John KarakkalVP of North American Sales & MarketingMs. Katherine TuminelloHR & Office Mang.More ExecutivesKey CompetitorsKymera TherapeuticsNASDAQ:KYMRBioCryst PharmaceuticalsNASDAQ:BCRXImmunovantNASDAQ:IMVTSpringWorks TherapeuticsNASDAQ:SWTXRelay TherapeuticsNASDAQ:RLAYView All CompetitorsInsiders & InstitutionsHarbor Capital Advisors Inc.Sold 3,276 shares on 1/20/2023Ownership: 0.033%Krish S KrishnanSold 22,149 sharesTotal: $1.79 M ($80.77/share)Suma KrishnanSold 22,148 sharesTotal: $1.79 M ($80.77/share)Hennion & Walsh Asset Management Inc.Bought 4,547 shares on 1/12/2023Ownership: 0.176%Krish S KrishnanSold 3,748 sharesTotal: $300,139.84 ($80.08/share)View All Insider TransactionsView All Institutional Transactions KRYS Stock - Frequently Asked Questions Should I buy or sell Krystal Biotech stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks. What is Krystal Biotech's stock price forecast for 2023? 3 brokers have issued 12-month price targets for Krystal Biotech's shares. Their KRYS share price forecasts range from $74.00 to $133.00. On average, they anticipate the company's stock price to reach $106.75 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts. How have KRYS shares performed in 2023? Krystal Biotech's stock was trading at $79.22 on January 1st, 2023. Since then, KRYS shares have increased by 6.3% and is now trading at $84.22. View the best growth stocks for 2023 here. Are investors shorting Krystal Biotech? Krystal Biotech saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,130,000 shares, an increase of 14.4% from the December 31st total of 988,100 shares. Based on an average trading volume of 174,600 shares, the days-to-cover ratio is currently 6.5 days. Currently, 5.4% of the shares of the company are short sold. View Krystal Biotech's Short Interest. When is Krystal Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our KRYS earnings forecast. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings results on Monday, November, 7th. The company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.23) by $0.06. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA). When did Krystal Biotech IPO? (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. What is Krystal Biotech's stock symbol? Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS." Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.18%) and Harbor Capital Advisors Inc. (0.03%). Insiders that own company stock include Krish S Krishnan and Suma Krishnan. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Krystal Biotech's stock price today? One share of KRYS stock can currently be purchased for approximately $84.22. How much money does Krystal Biotech make? Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $2.17 billion. The company earns $-69,570,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis. How many employees does Krystal Biotech have? The company employs 119 workers across the globe. How can I contact Krystal Biotech? Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com. This page (NASDAQ:KRYS) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.